The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10623 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin combination therapy

Not Open Access | Genomic Approaches to Drug Resistance in Malaria

September 10, 2020 - 14:21 -- NOT Open Access
Author(s): 
Rocamora F, Winzeler EA
Reference: 
Annu Rev Microbiol. 2020 Sep 8;74:761-786

Although the last two decades have seen a substantial decline in malaria incidence and mortality due to the use of insecticide-treated bed nets and artemisinin combination therapy, the threat of drug resistance is a constant obstacle to sustainable malaria control. Given that patients can die quickly from this disease, public health officials and doctors need to understand whether drug resistance exists in the parasite population, as well as how prevalent it is so they can make informed decisions about treatment.

Not Open Access | Dormant Plasmodium falciparum parasites in human infections following artesunate therapy

September 10, 2020 - 08:44 -- NOT Open Access
Author(s): 
Peatey C, Chen N, Gresty K, Anderson K, Pickering P, Watts R, Gatton ML, McCarthy J, Cheng Q
Reference: 
J Infect Dis. 2020 Sep 9:jiaa562

Artemisinin monotherapy of Plasmodium falciparum infection is frequently ineffective due to recrudescence. Artemisinin-induced dormancy, shown in vitro and in animal models, provides a plausible explanation. To date, direct evidence of artemisinin-induced dormancy in humans is lacking.

Significant efficacy of single low dose primaquine compared to stand alone artemisinin combination therapy in reducing gametocyte carriage in Cambodian patients with uncomplicated multidrug resistant Plasmodium falciparum malaria

March 19, 2020 - 09:13 -- Open Access
Author(s): 
Vantaux A, Kim S, Piv E, Chy S, Berne L, Khim N, Lek D, Siv S, Mukaka M, Taylor WR, Ménard D
Reference: 
Antimicrob Agents Chemother. 2020 Mar 16. pii: AAC.02108-19

Since 2012, single low dose of primaquine (SLDPQ, 0.25mg/kg) has been recommended with artemisinin-based combination therapies, as first-line treatment of acute uncomplicated Plasmodium falciparum malaria, to interrupt its transmission, especially in low transmission settings of multidrug, including artemisinin, resistance. Policy makers in Cambodia have been reluctant to implement this recommendation due to primaquine safety concerns and lack of data on its efficacy.

Subscribe to RSS - artemisinin combination therapy